

2025 Current Fiscal Year Report: Uniform Formulary Beneficiary Advisory Panel

Report Run Date: 08/02/2025 08:11:02 AM

1. Department or Agency

Department of Defense

2. Fiscal Year

2025

3. Committee or Subcommittee

Uniform Formulary Beneficiary
Advisory Panel

3b. GSA

Committee No.

9484

4. Is this New During Fiscal Year?

No

5. Current Charter

08/01/2024 08/01/2026

6. Expected Renewal Date

7. Expected Term Date

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

10 U.S.C. § 1074g(c)

13. Effective Date

10/05/1999

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program
Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open

0

17b. Closed

0

17c. Partially Closed

0

Other Activities

0

17d. Total

0

Meetings and Dates

No Meetings

Current Next
FY FY

18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$0.00	\$0.00
18e. Total Costs	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Panel will meet an estimate of four times a year to review and comment on the development of the Uniform Formulary by the DoD Pharmacy and Therapeutics Committee. The Director, Defense Health Agency is required to consider the comments of the panel before making his final decision.

20b. How does the Committee balance its

membership?

The Panel's membership includes family members of active duty and retired military personnel, members of retiree organizations, TRICARE healthcare contractors, and medical professionals from outside of DoD.

20c. How frequent and relevant are the Committee Meetings?

Per the Charter, the estimated number of Panel meeting is 4 per year. DoD implemented its Congressionally-mandated 3-tier Uniform Formulary (UF) in 2005 which required development of a transparent formulary management process that accesses medications for formulary status based on an evidence-based clinical and cost-effectiveness evaluation; open/equitable price competition; and to establish the Beneficiary Advisory Panel (BAP) which provides an opportunity for beneficiaries to comment on the DoD Pharmacy and Therapeutics Committee's formulary recommendations before approval by the DHA Director. The BAP concept is unique to DoD. It provides transparency and credibility from a beneficiary perspective to the UF process. Unlike private sector health plans, the DoD uses more disclosure of the evidence presented and allows beneficiaries to provide input before implementation of formulary changes. A major focus of the BAP is the process of formulary decision implementation, especially the process of communication with the 9.7 million TRICARE beneficiaries. For example, the BAP can recommend a longer implementation period for medications moved to Non-Formulary (Tier 3) to balance between allowing necessary time for beneficiary notification versus cost considerations. Moreover, feedback from the BAP was instrumental in the DoD's decision to start sending

targeted letters to affected beneficiaries during the up to 180-day implementation period.

Implementation periods have been lengthened on several occasions supporting communication with beneficiaries.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Mandated by law to review and comment on recommendations by the DoD Pharmacy and Therapeutics Committee regarding DoD's Uniform Formulary.

20e. Why is it necessary to close and/or partially closed committee meetings?

Meetings are not closed to the public unless the Department of Defense determines that items on the planned agenda meet the closed meeting provisions of 5 U.S.C. § 552b(c). Pursuant to DoD policy closed meetings can only be authorized by the DoD Sponsor (i.e., the Under Secretary of Defense for Personnel and Readiness), and only after consultation with the Office of the Department of Defense General Counsel.

21. Remarks

The number of recommendations submitted for FY23 was 1168 which was incorrect, the correct number was 1256. Title 10, U.S. Code, section 1074g(c), requires the Secretary of Defense to establish a Uniform Formulary Beneficiary Advisory Panel (BAP) under the Federal Advisory Committee Act. The estimated number of Panel meetings is four per year. The relationship between the committee and the decision maker is that no specific reports are submitted to the decision maker. Instead, the committee's advice and recommendations are communicated to the committee's decision maker through its meeting

minutes. The committee's decision maker reviews these minutes and makes appropriate decisions for the Department of Defense.

Designated Federal Officer

Tiffany F. Cline DFO

Committee Members	Start	End	Occupation	Member Designation
Dager, Karen	01/25/2022	04/25/2025	Health Net Federal Services	Special Government Employee (SGE) Member
Dailey, Holly	04/06/2022	04/25/2025	The Association of the United States Army	Special Government Employee (SGE) Member
Du Teil, John	01/25/2022	04/25/2025	United States Army Warrant Officers Association	Special Government Employee (SGE) Member
Guzman, Betsaida	01/25/2022	04/25/2025	Veterans of Foreign Wars	Special Government Employee (SGE) Member
McKeon, Joseph	01/25/2022	04/25/2025	Humana	Special Government Employee (SGE) Member
Meyers, Amanda	04/06/2022	04/25/2025	Military Officers Association	Special Government Employee (SGE) Member
Orfini, Patricia	04/06/2022	04/25/2025	National Family Member Association	Special Government Employee (SGE) Member
Ostrowski, Jon	01/25/2022	04/25/2025	Non-Commissioned Officers Association	Special Government Employee (SGE) Member
Peloquin, Jay	01/25/2022	04/25/2025	Express Scripts, Inc	Special Government Employee (SGE) Member

Schweitzer, Pamela	01/25/2023	04/25/2025	Pharmacist, COA-USPHS	Special Government Employee (SGE) Member
Soucy, Jennifer	01/25/2022	04/25/2025	United States Family Health Plan - Martins Point	Special Government Employee (SGE) Member

Number of Committee Members Listed: 11

Narrative Description

The Uniform Formulary Beneficiary Advisory Panel provides a forum for input into the development and sustainment of the pharmacy benefit for all Department of Defense (DoD) beneficiaries.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

None	<input checked="" type="checkbox"/>
Unable to Determine	<input type="checkbox"/>

Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

The recommendations made by the Panel do not attribute to a cost savings to the Department of Defense.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

1,368

Number of Recommendations Comments

The Panel made 112 recommendations during FY 2024, to address the FY 2024 DoD Pharmacy and Therapeutics Committee meetings. The Panel makes comments to the DoD Pharmacy and Therapeutics Committee recommendations for changes to the Uniform Formulary, implementation timelines, and prior authorization criteria. To date the Panel has made 1368 recommendations. This includes the 112 recommendations made in FY 2024. The number of recommendations submitted for FY23 was 1168 which was incorrect, the correct number was 1256.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

100%

% of Recommendations Fully Implemented Comments

The Director, Defense Health Agency, is required to consider the Panel's comments prior to her final decisions.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

The committee may recommend a shorter or longer implementation period. They may

also reject a recommendation. The Director, Defense Health Agency makes the final decision.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Minutes from the DoD Pharmacy & Therapeutics Committee and Uniform Formulary Beneficiary Advisory Panel are posted and available to Panel members.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

Access Comments

N/A